Prospective Clinical Study To Evaluate The Efficacy And Safety Of An Alexandrite Laser Device For The Treatment Of Acne Scars
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acne Scars
- Sponsor
- Cynosure, Inc.
- Enrollment
- 39
- Locations
- 2
- Primary Endpoint
- Photographic Evaluation of Changes in Treatment Areas
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The intended use of the Alexandrite laser device used in this study is to assess the efficacy and safety of the Alexandrite laser device for the treatment of acne scars on skin types V and VI.
Detailed Description
Subjects are to be enrolled in this clinical study if they are 18-65 years old. A maximum of 25 subjects will be enrolled at 1 study center. Subjects will receive up to 6 treatments (minimum of 4 treatment visits with an optional 5th and 6th treatment) on the face. Subjects will return for follow up visits at 30 and 90 days post last treatment. All subjects will receive a phone call 1 week after each treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A healthy male or female 18 - 65 years of age.
- •Has acne scars on the face (left, right, or front) and willing to undergo treatments with the study device.
- •Is a skin type V or VI.
- •Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
- •Understands and accepts the obligation and is logistically able to be present for all visits.
- •Is willing to comply with all requirements of the study and sign the informed consent document.
Exclusion Criteria
- •Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
- •The subject is hypersensitive to light in the near infrared wavelength region.
- •The subject takes medication which is known to increase sensitivity to sunlight.
- •The subject has seizure disorders triggered by light.
- •The subject takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
- •The subject has an active localized or systemic infection, or an open wound in area being treated.
- •The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated.
- •The subject has common acquired nevi that are predisposed to the development of malignant melanoma.
- •The subject has herpes simplex in the area being treated.
- •The subject is receiving or has received gold therapy.
Outcomes
Primary Outcomes
Photographic Evaluation of Changes in Treatment Areas
Time Frame: Baseline and 90 day follow up
Photographic evaluation with ECCA (échelle d'évaluation clinique des cicatrices d'acné) grading comparing pre-treatment images to the 90 day follow up images performed by independent reviewers. This scale gives higher scores based on the number of scars, with the description of the scars determining the weighting factor. The scale ranges from 0 to 540, with a lower score meaning less severe scarring.
Secondary Outcomes
- Subject satisfaction(90 day follow up)
- Photographic Evaluation of Treatment Areas(Baseline and 30 day follow up)
- Blinded evaluation of pre-treatment images vs. follow up images to determine which image is which(Baseline and 90 day follow up)
- Subject assessment using the Global Aesthetic Improvement Scale (SGAIS)(Baseline and 90 day follow up)
- Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS)(Baseline and 90 day follow up)